Date Added: 28/03/2017

Date Updated: 28/03/2017

Durvalumab (MEDI4736) for non-small cell lung cancer – adjuvant treatment following surgery

Specialties: Oncology & radiotherapy

Technology Type: Drugs

Stage of development: Investigational - phase III

Stage of EAA: Prioritised for assessment

This report is work in progress and should not be used for external distribution without permission from the originating agency. Users should be aware that reports are based on information available at the time of research and often on a limited literature search.